Measles | Jotup

96.4% of Americans had COVID-19 antibodies in their blood by fall 2022

Retrieved on:

Thursday, June 15, 2023

Vaccine, Infection, Vaccination, SARS-CoV-2, Coronavirus, COVID-19, Immunity, Antibody, Measles, Population, Blood, Serology, James Harrison (blood donor), Bias, PCR

Antibodies to SARS-CoV-2, the virus that causes COVID-19, were present in the blood of 96.4% of Americans over the age of 16 by September 2022.

Key Points:

Antibodies to SARS-CoV-2, the virus that causes COVID-19, were present in the blood of 96.4% of Americans over the age of 16 by September 2022.
And by identifying which kind of antibodies someone has in their blood, researchers can break down the 96.4% into different types of immunity: infection-derived, vaccine-derived and hybrid.
Researchers can tell that a person has been vaccinated and has not been infected if their blood has only anti-S antibodies that target that spike protein.
If someone has anti-N antibodies, which target the virus’s nucleocapsid protein, it’s a sign that they’ve been infected by SARS-CoV-2.

Long COVID could be caused by the virus lingering in the body. Here's what the science says

Retrieved on:

Saturday, June 10, 2023

When symptoms last longer than 12 weeks, the condition is known as long COVID.

Key Points:

When symptoms last longer than 12 weeks, the condition is known as long COVID.
Long COVID encompasses up to 200 different symptoms.
One factor that may be associated with long COVID is that the virus hasn’t fully cleared from the body after the initial infection.

Other viruses lurk in the body

This means the virus conceals itself within cells and remains dormant.
HIV, in particular, can remain dormant in infected cells throughout the body.
Several studies have shown COVID can also reactivate the Epstein-Barr virus, which has remained in the body in a latent state.

How do we know COVID stays in the body?

SARS-CoV-2 RNA was detected in at least half the samples of heart, lymph glands, eye, nerve, brain and lung tissue tested.
These patients had asymptomatic COVID and were PCR-negative from swabs of the nose and throat at four months.
Initial studies did not always suggest a strong relationship between the long-term detection of SARS-CoV-2 and long COVID symptoms.

How might the delay in clearing the virus impact people with long COVID?

We have previously shown immune dysfunction and inflammation persist up to eight months in people with long COVID that initially had mild to moderate disease.
Read more:
When does COVID become long COVID?
Antibodies reactive to Epstein-Barr virus are elevated in people with long COVID suggesting Epstein-Barr virus reactivation, likely through activating the immune system.
This should include examination of viral RNA and protein in both blood and tissues in people with long COVID independent of disease severity.

Phil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma Management

Retrieved on:

Tuesday, June 6, 2023

Software, Pharmaceutical, Data Management, IOT (Internet of Things), Apps, Applications, Technology, Medical Devices, Health Technology, Health Insurance, Biotechnology, Wearables, Mobile Technology, Practice Management, Health, Hypersensitivity, Anti-inflammatory, Salbutamol, Angioedema, Rash, Pain, Contraindication, Prednisone, Adrenal insufficiency, Digital health, Patient, Risk, Common, SVP, Arrhythmia, Hyperthyroidism, Wheeze, Physician, Urinary tract infection, Innovation, ICS, Measles, Hypertension, Vomiting, Back pain, System, Anaphylaxis, Trauma, Death, Moyamoya disease, Sinusitis, Allergy, Fungus, Fever, Eye, Hypokalemia, Record, Parasitism, Chickenpox, Medicine, LABA, Hives, Tuberculosis, Immune system, Milk, Heart rate, Bronchoconstriction, Blood pressure, Infection, Teva Pharmaceuticals, Gastroenteritis, Partnership, Diabetes, Tricyclic, Simplex, EMR, Fatality, Respiratory disease, Inc., Itch, Lactose, Bronchospasm, Immunosuppression, Fluticasone/salmeterol, Pharmaceutical industry, Generic drug, Vaccine, Medical device, Asthma

The goal of Phil and Teva Pharmaceuticals’ partnership is to help enable patients to receive and refill their Digihaler medication quickly, easily and affordably.

Key Points:

The goal of Phil and Teva Pharmaceuticals’ partnership is to help enable patients to receive and refill their Digihaler medication quickly, easily and affordably.
Using the PhilRx Patient Access Platform, patients can fill their prescription, review prescription records and obtain assistance navigating insurance benefits.
The PhilRx Patient Access Platform provides end-to-end visibility into the entire prescription life cycle, starting when the physician writes the prescription.
Physicians can select the PhilRx Patient Access Platform directly from an electronic medical record (EMR) to submit a prescription for a Digihaler product.

Join More than 20 Global Health and Safety Organizations Pledging Support to Mitigate Spread of COVID-19 and Other Infectious Diseases

Retrieved on:

Thursday, May 11, 2023

has attracted numerous businesses – as well as public health and occupational health and safety organizations – and provided them with free tools and resources to address these continued public health threats.

Key Points:

has attracted numerous businesses – as well as public health and occupational health and safety organizations – and provided them with free tools and resources to address these continued public health threats.
The latest employers to sign on as partners to the public education initiative Commit To C.A.R.E.
“This type of leadership speaks volumes about how businesses are committed to ensuring the health and safety of their employees and communities.
“If there’s one thing COVID-19 has taught employers it is that the spread of respiratory diseases cannot be underestimated.

RSV: we finally have a vaccine for this deadly virus

Retrieved on:

Tuesday, May 9, 2023

The first vaccine against respiratory syncytial virus (RSV) has been approved by the US Food and Drug Administration.

Key Points:

The first vaccine against respiratory syncytial virus (RSV) has been approved by the US Food and Drug Administration.
The European Medicines Agency is recommending the use of this vaccine, with a final decision likely to be made in July 2023.
Eventually, a key part of the virus, called F protein was identified as a likely vaccine target.
The Arexvy vaccine, developed by the UK-based pharmaceutical company GlaxoSmithKline, is known as a “protein subunit vaccine”.

Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023

Retrieved on:

Friday, May 5, 2023

STOCKHOLM, May 5, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") announced upcoming data presentations from the NeflgArd Phase 3 Study at the European Renal Association (ERA) Congress 2023.

Key Points:

STOCKHOLM, May 5, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") announced upcoming data presentations from the NeflgArd Phase 3 Study at the European Renal Association (ERA) Congress 2023.
"We are delighted that these data presentations have been selected for the upcoming ERA Congress 2023 and extend our congratulations to all the authors involved.
Poster presentation details are below and will be available on the Investor page on the Calliditas' corporate website following the meeting.
Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory clinical trial.

Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023

Retrieved on:

Friday, May 5, 2023

STOCKHOLM, May 5, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") announced upcoming data presentations from the NeflgArd Phase 3 Study at the European Renal Association (ERA) Congress 2023.

Key Points:

STOCKHOLM, May 5, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") announced upcoming data presentations from the NeflgArd Phase 3 Study at the European Renal Association (ERA) Congress 2023.
"We are delighted that these data presentations have been selected for the upcoming ERA Congress 2023 and extend our congratulations to all the authors involved.
Poster presentation details are below and will be available on the Investor page on the Calliditas' corporate website following the meeting.
Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory clinical trial.

Highlights - 23-29 April - European Immunisation Week - Subcommittee on Public Health

Retrieved on:

Tuesday, May 2, 2023

Motivation, Edible, Measles, DG, COVID-19, HPV, Communication, The United, Awareness, Social media, UNICEF, Vaccine, Vaccination

23-29 April - European Immunisation Week

Key Points:

23-29 April - European Immunisation Week
The European Immunisation Week took place from 23-29 April 2023 and we use this important occasion to communicate about the benefits of lifelong vaccination.
Following on from the joint statement from Commissioner Kyriakides, WHO/Europe and UNICEF on 24 April, we would like to invite you to support us and DG SANTE with communication on the following key messages:
- Vaccination is safe and every vaccine dose counts to protect you and those you love
- Check your national vaccination schedule and catch up on any missed doses as soon as possible
- Conversations about vaccination build understanding and motivation to follow vaccine recommendations and schedules
The United In Protection awareness raising communication campaign on the benefits of vaccination webpage includes translated toolkits with suggested messaging and edible social media assets on measles, HPV, COVID-19 and seasonal influenza, as well as links to other useful resources.
We would also like to take this opportunity to remind you of the European Vaccination Information Portal.

'Got polio?' messaging underscores a vaccine campaign's success but creates false sense of security as memories of the disease fade in US

Retrieved on:

Friday, April 28, 2023

Thanks, Science.” Messages like this are used in memes, posters, T-shirts and even some billboards to promote routine vaccinations.

Key Points:

Thanks, Science.” Messages like this are used in memes, posters, T-shirts and even some billboards to promote routine vaccinations.
Phrasing that aims to encourage immunizations by highlighting their accomplishments implies that some diseases are no longer a threat.
Moreover, a 2020 poll had found that 84% of adults viewed vaccinating children as important, a 10% decline from 2001.
A shift in focus to immunization in developing countries has further lulled Americans into a false sense of security.

Campaigning against a devastating disease

Before vaccines, polio – called infantile paralysis or poliomyelitis – was the most feared childhood disease in the U.S.
Frequently affecting elementary school kids, the disease sometimes presented like a cold or flu – fever, sore throat and headache.
Only time could reveal whether the paralysis was permanent or would recede, sometimes to return decades later as Post-Polio Syndrome.
High schoolers performed polio-themed plays, putting the disease itself on trial in “The People vs. Polio.” People passed around collection boxes at movie theaters and other public gatherings.

From public enemy No. 1 to success story

Over the next decade, the NFIP shifted its focus to widespread immunization, again using both mass media and local campaigns.
The repeated declaration of what polio vaccines could and were accomplishing was strategically effective in persuading more people to get their shots.
The American public of the 1960s and 1970s had lived through repeated polio epidemics and knew both the fear of contracting the disease and its visible aftereffects.
Public health rhetoric that focused on this vaccine success story worked around the world in the late 1980s and 1990s.
A reminder for the American public about this still dangerous disease can help ensure that “Got Polio?” does not become a serious question.

AANA Presents Health Leadership Award to U.S. Representative Brett Guthrie

Retrieved on:

Thursday, April 27, 2023

ROSEMONT, Ill., April 27, 2023 /PRNewswire/ -- The American Association of Nurse Anesthesiology (AANA) will recognize U.S. Representative Brett Guthrie (R-KY) as the winner of its National Health Leadership Award for 2023 at its Mid-Year Assembly, to be held in Washington, D.C., April 29-May 3.

Key Points:

ROSEMONT, Ill., April 27, 2023 /PRNewswire/ -- The American Association of Nurse Anesthesiology (AANA) will recognize U.S. Representative Brett Guthrie (R-KY) as the winner of its National Health Leadership Award for 2023 at its Mid-Year Assembly, to be held in Washington, D.C., April 29-May 3.
The National Health Leadership Award was established in 1992 and is presented to an individual working at the federal government level who has made a significant contribution to the formation of national health policy.
The award recognizes the individual's support in this process for the vital role that Certified Registered Nurse Anesthetists (CRNAs) play in providing access to cost-effective, quality anesthesia services.
"Through his tenure, Congressman Guthrie has been and continues to be a champion for access to healthcare," said AANA President Angela Mund, DNP, CRNA.